Introduction
To advance our understanding of breath as a source of biomarkers we must meld the measurement of breath in clinical and benchtop trials to a deeper understanding of disease pathogenesis. Exhaled volatile molecules represent the consequence of many biochemical processes and can be obtained easily, whereas the more common nucleic acid-or protein-based biomarkers reflect the possibility of those processes and require the collection of a sample. Regardless of the methodological approach, all 'omic-based fields still require a consideration of diverse factors, such as age, gender, and co-morbidities, which in turn can influence transcription, translation, epi-genetics, post-translational modifications, and consequently, small molecule production. Therefore, the search for breath-based biomarkers will benefit from systematic, in vitro experiments utilizing animal cell lines and/or microbial cultures in various metabolic states. The collection of articles in this Special Issue help us to link fundamental metabolic processes to the small molecules found in the breath of patients during disease.
What is in the issue?
Publications in this issue range from the characterization of volatile metabolites released directly from microbial culture, correlation or links to complex biochemical pathways, to bacterial culture links to ventilated patient breath.
Two papers investigated the impact of growth conditions on a single pathogen strain. Küntzel et al [1] focused on methodological factors influencing volatile molecules found in the headspace of cultures of the ungulate pathogen Mycobacterium avium ssp. paratuberculosis (MAP). After consideration of different growth media, the pattern of eight volatile molecules varied significantly amongst the different MAP strains. In addition, the effects of initial bacteria load and different periods of incubation on the release of volatile molecules was investigated. In a similar vein, Rees et al [2] investigated the volatile molecule profile produced by the opportunistic pathogen Klebsiella pneumonia after it was grown in human blood, a nutrient-poor medium that is reflective of bacteremia. The work generated nine novel compounds not previously seen in K. pneumonia cultures.
Two papers investigated the strain or species contribution to volatile molecule profiles in bacterial cultures. Bean et al [3] determined the inter-strain variation of the volatile metabolome of the opportunistic pathogen Pseudomonas aeruginosa. The 24 P. aeruginosa clinical isolates from a variety of infection sites were grown on a rich media and produced a core volatile molecule signature (70 molecules) with an additional 269 molecules produced that were not shared by all strains i.e., the pan volatilome. Dryahina et al [4] investigated the inter-species variation in the metabolome from a representative strain of four of the most common pathogens associated with lung infections in patients with cystic fibrosis. Three different media were used to culture Pseudomonas aeruginosa, Burkholderia cepacia, Staphylococcus aureus and Stenotrophomonas maltophilia. Twelve compounds differentiating those species under applied in vitro conditions were identified.
Some authors chose to focus on trying to link the biochemical pathways underlying production of volatile metabolites. Kleber et al [5] measured the breath of ventilated rats, focusing on the metabolism of Branched Chain Keto Acids (BCKA) in a liver of the rats with LPS-or TNF-induced inflammation, as profiled via cytokine analysis. The initial decrease in exhaled concentrations of 3-pentanone was correlated to the reuse of BCKA for the synthesis of new proteins. As inflammatory conditions persisted, a demand in cellular energy source substrates resulted in the degradation of excessive BCKA to propionyl-CoA reflected by later increase of the exhaled 3-pentanone. Bos et al [6] correlated the genotype-phenotype relationship for volatile molecule production by pathogenic bacteria. The KEGG database was interrogated using untargeted metagenomic sequences of bacterial DNA fragments from the sputum of CF patients in order to show that there is a plausible link between CF patients who produce acetaldehyde, ethanol and methanol and the resident metagenome. Phan et al [7] used stable isotope labeling (D-glucose-13 C 6 and 2 H 2 O) to evaluate the activity of metabolic pathways in Pseudomonas aeruginosa, Rothia mucilaginosa and Streptococcus salivarius. For example, tracking 13 C-labeled products demonstrated that despite of genetic capability of those bacteria, certain pathways remain metabolically inactive, e.g. in the glycolysis pathway, pyruvate was not converted to acetaldehyde (and further to ethanol) and instead pyruvate was metabolized to acetoacetate and further broken down to 2,3-butanedione. Stable isotope labeling is a valuable method for linking cause and effect in biological systems and will be a critical tool needed to advance breath biomarker biochemical pathway studies.
Some papers in the issue focused on clinical studies with diseased humans. In this regard, Leja et al [8] evaluated the contribution of the gut microbiome on the breath volatilome. Breath analysis from gastric cancer patients was used to assess the exhaled volatile molecules before and after Helicobacter pylori eradication via antibiotic therapy as well as before and after bowel cleansing. The increase of exhaled ethyl acetate and α-pinene in breath was observed after antibiotic eradication regimen, while acetone was increased in breath after bowel cleansing. Gao et al [9] linked their in vitro experiment with Acinetobacter baumannii to in vivo studies on mechanically-ventilated patients. They found 19 volatile molecules that discriminated between mechanically-ventilated patients without any infection or colonization, ventilated patients with A. baumannii colonization in the respiratory tract, and the ventilated patients suffering from ventilator-associated pneumonia caused by A. baumannii.
Summary
The original research articles published in this Special Issue on the Cellular origin of Volatile Metabolites provide examples of the many methodologies that can be employed to tackle this topic. In addition to these studies, there are other approaches that can be used to enhance our understanding of the biochemical origin of volatile molecules in exhaled breath, including sampling of metabolites from samples distal to the lung (e.g., directly or through biopsy) or the careful use of research animals. However, to link particular volatile molecules to pathogenesis processes, isotopically labeled probes coupled to other biochemical tools, such as inhibitors, will be necessary.
